Glenmar P. Obedencio

Author

Theravance Biopharma (United States)

Also Known As

G Obedencio, G.P. Obedencio, Glenmar Obedencio, Glenmar P Obedencio, Glenmar P. Obedencio, Obedencio, Glenmar P.

Publications

306

Citations

H-Index

Concepts

All Affiliations

Theravance Biopharma (United States)

About

Glenmar P. Obedencio is an author at Theravance Biopharma (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	225
2	Health Sciences	3	3	129
3	Allergy	1	1	12
4	Gastroenterology	1	1	12
5	Immunology	1	1	12

Glenmar P. Obedencio

Publications

279

Citations

H-Index

Page 1

	Year	Citations
Efficacy of Telavancin (TD-6424), a Rapidly Bactericidal Lipoglycopeptide with Multiple Mechanisms of Action, in a Murine Model of Pneumonia Induced by Methicillin-Resistant <i>Staphylococcus aureus</i> Noe Reyes, Robert Skinner, Koné Kaniga, Antimicrobial Agents and Chemotherapy Microbial PathogensMultiple MechanismsPharmacotherapyAntimicrobial ChemotherapyDrug Resistance	2005	76
5-HT4 receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment Fei Shen, Jacqueline A.M. Smith, Ray Chang, Neuropharmacology Neurodegenerative DiseasesAlzheimer's Disease5-Ht4 Receptor AgonistMedicineNeurochemical Biomarkers	2011	74
Pharmacodynamics of TD-1792, a Novel Glycopeptide-Cephalosporin Heterodimer Antibiotic Used against Gram-Positive Bacteria, in a Neutropenic Murine Thigh Model Sharath S. Hegde, Ólanrewaju O. Okusanya, Robert Skinner, Antimicrobial Agents and Chemotherapy GlycobiologyStaphylococcus AureusAntimicrobial ChemotherapyDrug ResistanceGram-positive Bacteria	2011	30
In Vivo Pharmacological Characterization of TD-4208, a Novel Lung-Selective Inhaled Muscarinic Antagonist with Sustained Bronchoprotective Effect in Experimental Animal Models M. Teresa Pulido‐Rios, Alexander McNamara, Glenmar P. Obedencio, Journal of Pharmacology and Experimental Therapeutics	2013	28
Relative Contributions of Norepinephrine and Serotonin Transporters to Antinociceptive Synergy between Monoamine Reuptake Inhibitors and Morphine in the Rat Formalin Model Fei Shen, Pamela R. Tsuruda, Jacqueline A.M. Smith, PLoS ONE NeuropeptidesRat Formalin ModelPain MedicineMolecular PainPharmacotherapy	2013	23
Prediction of Human Serotonin and Norepinephrine Transporter Occupancy of Duloxetine by Pharmacokinetic/Pharmacodynamic Modeling in the Rat David L. Bourdet, Pamela R. Tsuruda, Glenmar P. Obedencio, Journal of Pharmacology and Experimental Therapeutics	2012	16
Gut-Selective Design of Orally Administered Izencitinib (TD-1473) Limits Systemic Exposure and Effects of Janus Kinase Inhibition in Nonclinical Species Rhiannon N. Hardwick, Patrick Brassil, Ilaria Badagnani, Toxicological Sciences ImmunotoxicologyGastrointestinal PharmacologyImmunologyGastroenterologyPharmacotherapy	2022	12
Duration by Design: Discovery of Revefenacin, the First-in-Class Nebulized Once-Daily Bronchodilator for the Treatment of Patients With COPD Yuhua Ji, Craig Husfeld, M. Teresa Pulido‐Rios, CHEST Journal AsthmaPulmonary CareAdvanced Lung DiseasePulmonary PharmacologyPulmonary Medicine	2016	10
Discovery of N-substituted-endo-3-(8-aza-bicyclo[3.2.1]oct-3-yl)-phenol and -phenyl carboxamide series of μ-opioid receptor antagonists Lan Jiang, David T. Beattie, John R. Jacobsen, Bioorganic & Medicinal Chemistry Letters	2017	10

Page 1